Original Research

There are numerous opportunities to improve quality in the prescribing and monitoring of patients receiving oral anticancer medications.
Emily R. Mackler, PharmD, BCOP, Oncology Clinical Pharmacist, Michigan Oncology Quality Consortium at the University of Michigan Comprehensive Cancer Center, and Adjunct Clinical Associate Professor at the University of Michigan College of Pharmacy, Ann Arbor, discusses the clinical significance of her study, “Implementation of and Satisfaction with an Outpatient Oral Anticancer Therapy Program.”
Oral chemotherapy utilization and availability have increased in the past several years. Of the new oncologic agents in development, 30% to 35% are oral preparations.1 With the increasing development of new oral anticancer therapies, there have also been growing concerns regarding adherence, toxicity, and cost.
Review this study that aims to quantify the use of oral anticancer agents and analyze the incidence of various drug-related problems among patients treated with these medications.
Trace the overall management of a fluorouracil overdose from initial exposure, through hospitalization and posthospitalization, to recovery.
With advances in technique and supportive care, bone marrow transplant (BMT) patients have a longer life expectancy now than when BMT was first performed more than 40 years ago. Despite much higher mortality rates than the general population, up to 80% of BMT patients who survive 5 years posttransplantation will be alive 20 years posttransplantation. However, patients who live longer can be at higher risk for complications, in part because of changes in their body’s immune system. One of these concerns is the loss of immunity that was previously achieved through vaccination. To regain immunity to vaccine-preventable diseases, including measles, mumps, hepatitis, and diphtheria, patients need to be revaccinated following BMT.
Recent statistics from the National Cancer Institute estimate that 25% of adults with acute myeloid leukemia (AML) are expected to survive for ≥3 years. Depending on other prognostic factors, such as duration of first remission, age, performance status, cytogenetics, and prior hematopoietic stem cell transplant, the overall survival of patients with relapsed/refractory disease at 5 years was
Malignancy is a significant risk factor for venous thromboembolism (VTE), conferring a 4- to 7-fold increased risk in patients with cancer
It is important that patients treated with chemotherapy be educated about what to expect from their regimen and the correct use of supportive care medications at home.
Angiogenesis, the development of new blood vessels from preexisting vessels, is considered to be one of the central “hallmarks” in most malignancies.
Page 3 of 5
Results 21 - 30 of 44